Gd-EOB-DTPA增强MRI无创短期评估丙型肝炎DAA治疗后肝脏坏死性炎症
前瞻性纳入21例慢性丙型肝炎患者,在DAA治疗前和治疗后24周行Gd-EOB-DTPA增强MRI和肝活检,以Ishak评分分级坏死性炎症。结果显示治疗后CEI、RE和ADC显著升高,CEI与坏死性炎症分级相关(r=-0.596),CEI联合ADC鉴别G0-6与G7-18的AUROC为0.837。
要点
- Gd-EOB-DTPA增强MRI的CEI可无创评估DAA治疗后肝脏坏死性炎症分级。
- CEI联合ADC鉴别无/轻度与中/重度坏死性炎症的AUROC达0.837。
- 治疗后24周CEI、RE和ADC较基线显著升高,提示炎症改善。
关键影像表现/征象
- DWI采用屏气单次激发回波平面自旋回波序列采集。
- Gd-EOB-DTPA给药后20分钟记录相对强化(RE)和对比强化指数(CEI)。
- 治疗后24周CEI、RE和ADC较基线显著升高(p=0.0004、0.0032、0.0110)。
- CEI与坏死性炎症分级呈负相关(r=-0.596,p=0.006)。
诊断标准与关键数值
- CEI、ADC在坏死性炎症不同组织学分级间差异有统计学意义(p=0.006和0.036)。
- CEI鉴别G0-6与G7-18的AUROC为0.834(95%CI 0.712-0.956)。
- ADC鉴别G0-6与G7-18的AUROC为0.724(95%CI 0.565-0.884)。
- CEI联合ADC鉴别G0-6与G7-18的AUROC为0.837(95%CI 0.717-0.956)。
临床应用与阅片要点
- 可利用Gd-EOB-DTPA增强MRI的CEI无创评估DAA治疗后肝脏坏死性炎症活动程度。
- CEI联合ADC可提高鉴别无/轻度与中/重度坏死性炎症的 diagnostic 准确性。
- 阅片时关注肝胆期20分钟的相对强化和对比强化指数变化。
局限性
- 样本量较小(最终队列21例)。
- 单中心前瞻性研究。
- 仅评估短期(24周)变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess liver necroinflammation in HCV patients undergone antiviral therapy by Gd-EOB-DTPA-enhanced MRI with histopathologic analyses as reference.
METHODS: HCV patients were enrolled in this prospective study before antiviral treatment between 09-2016 and 07-2017. Unenhanced MR, Gd-EOB-DTPA-enhanced MR, and liver biopsy were performed before and 24 weeks after treatment of daclatasvir with asunaprevir (DAA). DWI was obtained using a breath-hold single-shot echo planar spin-echo sequence. Twenty minutes after administration of Gd-EOB-DTPA, the relative enhancement (RE) and the contrast enhancement index (CEI) were recorded. Liver necroinflammatory activity grades (G0-18) were categorized on the Ishak Scoring systems. CEI, RE, and DWI of baseline and 24 weeks after treatment were compared by paired t test. Relationship between MR parameters and histologic scores was evaluated by Pearson's correlation. Receiver operating characteristic analysis evaluated the measurements' diagnostic performance. MRI variability between two readers was assessed using the intraclass correlation coefficient.Results RESULTS: A decrease of liver necroinflammatory activity grade (p < 0.0001) was detected in final cohort (n = 21; mean age 44 years; 23 to 67 years; 11 F, 10 M). Statistical results of 42 person-times in 21 patients at baseline and follow-up showed CEI and ADC were significantly different (p = 0.006 and 0.036) across histologic grades of liver necroinflammation. Significant increase of CEI, RE, and ADC (p = 0.0004, 0.0032, 0.0110) 24 weeks after DAA treatment was seen. Additionally, CEI was correlated to necroinflammatory grade (r = - 0.596, p = 0.006). AUROC for CEI, ADC, and CEI combined with ADC to differentiate patients with none and mild (G0-6) from patients with moderate and severe necroinflammation (G7-18) was 0.834 (95% CI 0.712-0.956, 0.724(95% CI 0.565-0.884) and 0.837(95% CI 0.717-0.956).
CONCLUSION: Gd-EOB-DTPA-enhanced MRI by CEI could be used as a noninvasive imaging biomarker to distinguish grades of necroinflammatory activity in patients with HCV after DAAs therapy at early stage and CEI combined with ADC could get a better diagnostic accuracy.
引用
- Li A, Wu J, Cheng J, et al. Gd-EOB-DTPA-enhanced MRI-a noninvasive and short-term assessment method for liver necroinflammation after direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C. Abdom Radiol (NY). 2021. PMID: 34664096. doi:10.1007/s00261-021-03316-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。